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Abstract K-methyl-p-tyrosine (KMPT), an inhibitor of tyrosine
hydroxylase, was administered to mice to block noradrenaline
synthesis. Ten hours after injection of KMPT there was a 6-fold
increase in plasma leptin. The level of ob mRNA in epididymal
white adipose tissue was also increased, but UCP1 mRNA in
brown fat fell. In contrast to lean mice, ob mRNA in white fat of
ob/ob mice was not increased by KMPT. KMPT raised plasma
leptin in fasted as well as fed mice. Hyperleptinaemia was
attenuated by treatment with a L3-adrenoceptor agonist.
Inhibition of noradrenaline synthesis leads to the rapid induction
of hyperleptinaemia; it is suggested that sympathetic tone plays a
pivotal role in regulating leptin production.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Leptin, the protein product of the ob (obese) gene, is a
16 000 Mr hormone, whose principle site of synthesis is white
adipose tissue [1], although it is now evident that it is also
produced in brown fat [2^4] and the placenta [5,6]. Leptin is
considered to be a signalling molecule to the brain in the
regulation of whole-body energy balance [1,7^9] and in con-
veying the extent of the adipose tissue stores for the initiation
of reproduction [10,11]. It is also increasingly recognised that
leptin is an important metabolic hormone, in£uencing proc-
esses such as insulin secretion and glucose utilisation [12,13].
A key issue is how the production of leptin is regulated, and a
number of factors which in£uence the synthesis of the hor-
mone by white adipose tissue have been identi¢ed; these in-
clude fasting, catecholamines, insulin, dexamethasone and
thiazolidiones [14^20].
Noradrenaline, isoprenaline and L3-adrenoceptor agonists
have a powerful inhibitory e¡ect on ob gene expression and
induce a rapid fall in circulating leptin [15,21^23]. From this it
is suggested that the sympathetic nervous system is involved in
a negative feedback loop to adipose tissue regulating ob gene
transcription through L3-adrenoceptors [23^25], and we have
recently hypothesised that physiologically the sympathetic sys-
tem may be the pivotal regulator of leptin production [25].
This proposition has parallels with the central role long at-
tributed to the sympathetic system in the regulation of lip-
olysis in white fat [26,27].
In the present report we show that treatment with K-meth-
yl-p-tyrosine (KMPT), a speci¢c inhibitor of tyrosine hydrox-
ylase [28], the rate limiting enzyme in the synthesis of nor-
adrenaline, leads to a rapid and substantial increase in
circulating leptin. This appears to be due to an increase in
ob gene transcription, resulting from the inhibition of normal
sympathetic tone.
2. Materials and methods
2.1. Animals
Male mice, aged 8 weeks, were used in this study. They were either
of the Aston variety, both lean (+/?) and obese (ob/ob), from a colony
bred at the Rowett Research Institute, or of the C57BL/6J strain
(Harlan Olac). They were housed at 22‡C in a room with a 12 h
light/12 h dark cycle (lights on at 07:00 h) and fed a commercial
rodent diet (Biosure; Special Diet Services) containing 18% protein
and 2.4% fat (w/w). The animals were given ad libitum access to both
food and water.
In the majority of experiments mice were injected intraperitoneally
with KMPT (methyl ester, Sigma; 300 mg/kg body wt) [29] in saline
(0.9% NaCl) at 0 and 5 h, with the control animals receiving injections
of saline alone. Blood was taken and the animals killed by cervical
dislocation at 10 h after the ¢rst injection. Epididymal (and subcuta-
neous) white adipose tissue, together with the interscapular brown fat
pads, were rapidly removed and frozen in liquid nitrogen. Blood was
collected into heparinised tubes and centrifuged to obtain the plasma.
The plasma was stored at 380‡C until analysed for leptin.
In some experiments, mice were treated with BRL 35135A (a gift
from SmithKline Beecham Pharmaceuticals) as well as with KMPT.
The L3-adrenoceptor agonist was injected subcutaneously at a dose of
750 Wg/kg body wt at 0 and 5 h (at the same time as KMPT) and
tissues removed at 10 h. Control mice received injections of saline
alone.
In one experiment mice were fasted for 24 h in cages with wire-mesh
£oors, and KMPT (or saline) injected at 6, 14 and 19 h after the
removal of food. Control mice were given free access to food and
received KMPT or saline. At 24 h after the start of the experiment,
tissues and blood were removed.
2.2. Northern blotting
Total RNA was extracted from adipose tissue using a guanidium
isothiocyanate-phenol method, and separated according to size by
agarose gel electrophoresis [14,15]. The RNA was blotted onto a
nylon membrane (Boehringer Mannheim) by vacuum blotting and
¢xed with UV light. ob mRNA was detected by a chemiluminescence
procedure, utilising a 33-mer antisense oligonucleotide (5P-
GGTCTGAGGCAGGGAGCAGCTCTTGGAGAAGGCP) probe
end-labelled (5P) with digoxigenin (Boehringer Mannheim), as de-
scribed previously [14,15]. A similar procedure was used for the de-
tection of UCP1 mRNA, using a 32-mer antisense oligonucleotide (5P-
CGGACTTTGGCGGTGTCCAGCGGGAAGGTGAT) [15]. The
oligonucleotides were synthesised commercially (Oswel DNA Serv-
ices).
Hybridisation was performed overnight at 42‡C in pre-hybridisa-
tion bu¡er containing the antisense oligonucleotide (25 ng/ml). Post-
hybridisation washes were performed as previously [14,15], and the
membranes then incubated with an anti-digoxigenin Fab/alkaline
phosphatase conjugate (Boehringer Mannheim). CDP-Star (Tropix)
was used as the chemiluminescence substrate. Signals were detected
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on ¢lm and quanti¢ed by densitometry. After exposure to ¢lm (5^60
min) the membranes were stripped and re-probed for 18S rRNA using
a 31-mer digoxigenin-labelled antisense oligonucleotide (10 pg/ml)
[15].
2.3. Immunoassay for leptin
Plasma leptin was measured by a sandwich enzyme-linked immu-
nosorbent assay (ELISA) [20] employing a rabbit anti-murine leptin
IgG prepared at the Rowett. A detection limit of 100 pg of leptin/ml
was achieved by utilising a biotin-avidin sensitivity enhancing system
[20]. A recombinant murine leptin standard (R and D Systems
Europe) was used in the assay.
2.4. Data analysis
The statistical signi¢cance of di¡erences between groups was as-
sessed by Student’s unpaired t-test. Densitometric data from Northern
blots were normalised to control mice, which were assigned an arbi-
trary value of 1. mRNA levels were corrected for di¡erences in gel
loading or blotting by reference to the level of 18S rRNA.
3. Results
KMPT was administered at dose levels and in a protocol
similar to that employed in studies on the turnover of nor-
adrenaline in tissues [28^30]. Administration of KMPT to mice
led to a 6-fold increase in the level of plasma leptin by 10 h
after the ¢rst of the two injections (Fig. 1). The level of ob
mRNA was then examined in the epididymal white adipose
tissue to determine whether treatment with KMPT led to
changes in ob gene expression. The treated mice exhibited a
3-fold increase in the level of ob mRNA compared with the
untreated animals (Fig. 2a). There was also an increase (1.4-
fold) in ob mRNA in the subcutaneous adipose tissue of the
treated animals, but the level of the mRNA in this fat depot
was very low and the increase was not statistically signi¢cant
(Ps 0.05; results not shown).
UCP1 mRNA in interscapular brown adipose tissue was
also examined following the administration of KMPT. Treat-
ment with the drug led to a substantial fall in UCP1 mRNA
level, to one-third of that in untreated animals (Fig. 2b).
When KMPT was administered to obese (ob/ob) mice, there
was no increase in ob mRNA in epididymal white fat, in
contrast to lean animals; indeed, there was a small, though
not statistically signi¢cant, decrease (Fig. 3).
In the next experiment, mice treated with KMPT were also
injected with a selective L3-adrenoceptor agonist, BRL
35135A, to determine whether this would counter the hyper-
leptinaemia induced by KMPT. The administration of BRL
35135A alone to untreated mice led to a reduction in circulat-
ing leptin (Fig. 4). In the mice treated simultaneously with
KMPT, BRL 35135A produced a signi¢cant attenuation in
the circulating level of leptin, although it was not restored
to normal (Fig. 4).
Fasting is associated with a fall in circulating leptin [20],
and this was also observed in the present study (Fig. 5). How-
ever, the administration of KMPT reversed the fasting-in-
duced decrease in plasma leptin. Indeed, the leptin levels of
the fasted animals treated with KMPT were elevated to values
similar to those of the treated fed mice (Fig. 5).
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Fig. 1. E¡ect of KMPT on plasma leptin in mice. Mice were in-
jected with KMPT at 0 and 5 h and blood taken at 10 h. The re-
sults are given as mean values þ S.E. (bars) for eight mice in each
group. **P6 0.01, compared with control mice.
Fig. 2. E¡ect of KMPT on (a) ob mRNA level in epididymal white
adipose tissue and (b) UCP1 mRNA level in interscapular brown
fat of mice. Mice were treated as in Fig. 1. Representative Northern
blots are shown in the upper panel of (a) and (b). The lower panels
show the quanti¢cation of mRNA levels expressed relative to the
controls, with the results given as mean values þ S.E. (bars) for six
mice in each group. **P6 0.01, ***P6 0.001, compared with con-
trol mice.
Fig. 3. E¡ect of KMPT on ob mRNA level in epididymal white adi-
pose tissue of ob/ob mice. Mice were treated as in Fig. 1. Represen-
tative Northern blots are shown in the upper panel. The lower panel
shows the quanti¢cation of mRNA levels expressed relative to the
controls, with the results given as mean values þ S.E. (bars) for eight
mice in each group.
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4. Discussion
The present study demonstrates that administration of
KMPT to mice leads to the rapid induction of a substantial
hyperleptinaemia, with plasma leptin levels being increased
several-fold a few hours after the injection of the compound.
Increases in circulating leptin could, in principle, be due to a
reduction in clearance or to a stimulation of the production of
the hormone. Since there was a marked elevation in the level
of ob mRNA in the epididymal white adipose tissue of mice
treated with KMPT, it is apparent that increases in production
underlie the induction of the hyperleptinaemia.
KMPT is a potent and speci¢c inhibitor of tyrosine hydrox-
ylase, the rate limiting enzyme in the synthesis of noradrena-
line, and it has been widely used as a tool in the measurement
of sympathetic activity [28^30]. By inhibiting synthesis, the
rate of noradrenaline depletion provides an index of sympa-
thetic activity in a given tissue. However, depletion of nor-
adrenaline by KMPT also leads to sympathetic blockade.
Thus the probable mechanism by which KMPT a¡ects leptin
production is through a reduction in noradrenaline synthesis,
and hence a consequent decrease in the tonic sympathetic
stimulation of white adipose tissue. Expression of the UCP1
gene in brown fat is stimulated by the sympathetic system [31],
and the concomitant fall in the level of UCP1 mRNA in
treated animals indicates that KMPT was having its expected
pharmacological e¡ect.
Previous studies have shown that noradrenaline and iso-
prenaline strongly inhibit leptin production, this occurring
through the suppression of ob gene expression [15]. These
catecholamines operate via L3-adrenoceptors, L3-agonists
being potent inhibitors of leptin production [21^25]. Thus it
is probable that KMPT leads to an increase in circulating
leptin levels by blocking the sympathetically mediated sup-
pression of ob gene expression. The increase in plasma leptin
induced by KMPT was attenuated by simultaneous treatment
with BRL 35135A, a selective L3-adrenoceptor agonist, and
this is consistent with the L3-agonist directly substituting for
the reduced sympathetic activity consequent upon the inhib-
ition of noradrenaline synthesis.
Fasting leads to a substantial fall in both ob gene expression
and in circulating leptin levels [14,16,20]. Treatment with
KMPT not only reversed the fasting-induced reduction in lep-
tin, but led to a substantial increase, similar to that in the fed
mice. It has recently been shown by direct measurements of
noradrenaline turnover that fasting results in a selective acti-
vation of the sympathetic stimulation to white adipose tissue
[32], sympathetic activity in other tissues such as brown fat
and the heart being decreased in the fasted animal [30]. It has
been proposed subsequently that the inhibitory e¡ects of fast-
ing on leptin production are mediated primarily through the
increase in sympathetic activity in white fat [24,25].
Treatment with KMPT did not lead to a rise in the level of
ob mRNA in obese ob/ob mice, which lack functional leptin.
These animals exhibit a substantial reduction in L3-adreno-
ceptor mRNA in white fat relative to lean mice where the
level of this mRNA is much higher than that of the mRNAs
encoding L1- or L2-adrenoceptors [33]. ob/ob mice also show a
marked blunting in the stimulation of adenyl cyclase activity
by L3-agonists [34]. Thus in these mutants the inhibition of
sympathetic stimulation in white fat induced by KMPT would
not be expected to lead to the increase in ob mRNA level seen
in the normal mouse. This is also consistent with the absence
of a suppressive e¡ect of fasting on ob mRNA levels in ob/ob
mice [14], if the view is correct that sympathetic activation in
white fat is the primary cause of the fall in ob gene expression
in the fasted animal.
In addition to being a tool for the measurement of sympa-
thetic activity in peripheral tissues, KMPT has been used clin-
ically to treat the hypertension of patients with phaeochromo-
cytoma, a tumour of the adrenal medulla which leads to a
hypersecretion of catecholamines. It is conceivable, therefore,
that the induction of hyperleptinaemia by KMPT could partly
occur through a depletion of circulating adrenaline, with ad-
renaline playing a role in the catecholamine-induced suppres-
sion of ob gene expression in white fat.
In conclusion, the central implication of the ¢ndings re-
ported here is that expression of the ob gene and the resultant
production of leptin may normally be constrained by the tonic
activity of the sympathetic system ^ most probably directly
through the sympathetic innervation of white adipose tissue.
The results suggest that KMPT may be a useful pharmacolog-
ical tool for investigating the consequences of chronic hyper-
leptinaemia. They also suggest that the use of KMPT to meas-
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Fig. 5. E¡ect of KMPT on plasma leptin in fasted mice. Mice were
fasted for 24 h and injected with KMPT at 6, 14 and 19 h after the
initiation of the fast, and blood taken at 24 h. Control mice were
given free access to food. The results are given as mean val-
ues þ S.E. (bars) for eight mice in each group. **P6 0.01,
***P6 0.001, compared with control mice; 222P6 0.001, compared
with the fasted group.
Fig. 4. E¡ect of the L3-adrenoceptor agonist BRL 35135A on plas-
ma leptin in mice treated with KMPT. Mice were injected with ei-
ther BRL 35135A, KMPT, or BRL 35135A plus KMPT, at 0 and
5 h and blood taken at 10 h. Control mice received saline injections.
The results are given as mean values þ S.E. (bars) for seven mice in
each group. *P6 0.05, ***P6 0.001, compared with control mice;
2P6 0.05, compared with the KMPT treated group.
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ure sympathetic activity may be problematic since leptin itself
is known to stimulate sympathetic activity [35].
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